3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Head & Neck
1
Conditions
Leukemia, Myeloid, Acute
16
Myelodysplastic Syndromes
9
Lung Neoplasms
5
Myeloproliferative Disorders
4
Leukemia, Myelomonocytic, Chronic
4
Sarcoma
3
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Head and Neck Neoplasms
3
Breast Neoplasms
3
Stomatitis
2
Primary Myelofibrosis
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Mucositis
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Leukemia, Monocytic, Acute
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia, Biphenotypic, Acute
2
Disease
2
Carcinoma, Non-Small-Cell Lung
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thrombocythemia, Essential
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Synovial
1
Prostate Cancer Metastatic
1
Polycythemia Vera
1
Interventions
Cisplatin
7
Cetuximab
6
Radiotherapy, Intensity-Modulated
4
pembrolizumab
3
durvalumab
3
Radiotherapy
2
Radiation
2
Observation
2
Drug Therapy
2
Celecoxib
2
Bupropion
2
130-nm albumin-bound paclitaxel
2
trametinib
1
sodium thiosulfate
1
gluconic acid
1
ficlatuzumab
1
Zinc
1
Watchful Waiting
1
Varenicline
1
Transcutaneous Electric Nerve Stimulation
1
Tobacco Use Cessation Devices
1
Tadalafil
1
Sirolimus
1
RRx-001
1
Psychiatric Rehabilitation
1
Polymerase Chain Reaction
1
Pilocarpine
1
Photochemotherapy
1
Periodontal Debridement
1
Oral Hygiene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Mouth Neoplasms
×
Injections
×
Clear all
NCT03515538
2024-11-04
PREVLAR
EpicentRx, Inc.
Phase 2
Completed
53 enrolled
15 charts